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Abstract
Objective. Multi-drug resistant bacterial infections, in particular when
Methicillin-Resistant Staphylococcus Aureus (MRSA) is involved, have
become a relevant problem in both general and specialized intensive care
units. The aim of this study was to identify the epidemiology of MRSA
infections in a Cardiac Surgical Intensive Care Unit, to assess their
impact on mortality and to identify predictors of MRSA infection and
mortality in this population.
Design and settings. A 7-year observational study in a cardiac surgery
teaching center.
Participants. Eight thousand, one hundred and sixty-two microbiological
samples were obtained from 7,313 patients who underwent cardiac
surgery in the study period.
Interventions. None.
Variables of interest and main results. Twenty-eight patients (0.38%) had
MRSA infection. The most frequent site of MRSA isolation was from
bronchoalveolar samples. Hospital mortality was 50% in patients with
MRSA infection and 2% in patients without MRSA infection (p<0.001).
Few preoperative independent predictors of MRSA infection and hospital
mortality were found at multivariate analysis. Outcomes were found to be
most influenced by perioperative variables. MRSA infection was the
strongest predictor of mortality, with an odds ratio of 20.5 (95% CI 4.143-
101.626).
Conclusions. Methicillin-resistant Staphylococcus aureus infections
following cardiac surgery still have a strong impact on the patients’
outcome. More efforts should be directed toward the development of new
risk analysis models that might implement health care practices and
might become precious instruments for infection prevention and control.
Key words: Methicillin-Resistant Staphylococcus Aureus, infections,
cardiac surgery, mortality, intensive care, cardiac anaesthesia
Introduction
Despite considerable improvements in surgical techniques and antibiotic
therapies in the last decades, Healthcare Associated Infections (HAI) in
surgical patients admitted to Intensive Care Units (ICU) continue to be
among the most severe complications, especially after cardiac surgery.
(1,2)
Infections after cardiac operations are associated with poor outcomes,
including elevated readmission rates, prolonged hospital stay, higher rate
of surgical revisions, administration of antibiotics, and adoption of
resources that comply with higher health care costs and mortality. (1,2)
Among the various species of pathogens involved, Staphylococcus aureus
strongly impacts on the outcomes of these patients. Methicillin-resistant
Staphylococcus aureus (MRSA) infections have become a relevant
problem in cardiac surgery because of their multidrug-resistant profile,
virulence and disease spectrum.
All over the world, ICUs may a have a role in the selection of resistant
microbiological strains. Therefore, a strict surveillance system, to prevent
the spread of these strains, is a major public health challenge and often
requires several institutional efforts. (3-7)
The aim of this study was to identify the epidemiology of MRSA strains
among the microbiologic isolates in a Cardiac Surgical Intensive Care
Unit over a 7-year period, to assess its impact on mortality and to identify
predictors of MRSA infection and mortality in this population. These
results will be commented in the light of similar data reported by our
study group on a similar population of cardiac surgery patients in the
past. (1)
Patients and methods
The study was conducted in compliance with the Declaration of Helsinki
and had the approval of the local ethical committee. We analyzed data of
patients who underwent cardiac surgery at San Raffaele Scientific
Institute over a seven-year period. Our teaching hospital has 3 cardiac
surgery operating rooms, and a 14 bed dedicated ICU. All patients
underwent cardiac surgery under general anesthesia and were
transferred, intubated, to the ICU.
All patients received standard postoperative intravenous therapy,
including hydration, antacids and diuretics, together with inotropes and
devices, if needed.
Similarly, intravenous antibiotic prophylaxis was performed shortly after
the induction of general anesthesia and maintained for the first 48 hours
postoperatively: 2 g of cefazolin was used as an induction bolus (in
patients with known allergy to beta-lactams, either vancomycin 1 g or
clindamycin 600 mg were used), and 1 g 3 times a day was the standard
maintenance dose (or vancomycin 500 mg 4 times a day).
Infection was suspected if a patient developed fever (body temperature
T>38 C°), an increase in white blood cell count, changes in the chest X-
ray consistent with pneumonia, worsening of respiratory function not
due to cardiogenic pulmonary oedema or a new increase in C reactive
protein.
When an infection was suspected, 3 sets of blood cultures, deep tracheal
aspirate or bronchoalveolar lavage, and urine samples were sent to the
laboratory for microbiological examination.
In addition, if an intravascular device infection was suspected, the device
was changed or removed and the tip was sent for microbiological
investigation.
If considered appropriate, a wide spectrum antibiotic was initiated before
completion of microbiological tests.
Generic prophylactic measures were routinely applied, such as hand
washing and use of gloves. No specific prophylactic measures were
routinely adopted (i.e. preoperative screening of Staphylococcus species
carriers, screening of medical staff, application of topical chlorhexidine).
Hemodynamic monitoring was performed for each patient according to
clinical needs. Acute kidney damage was diagnosed in the presence of an
increase in serum creatinine value of 50% or a decrease in glomerular
filtration rate of 25%, compared to preoperative data. (8) Creatinine
clearance was estimated according to the Cockroft-Gault equation (9) and
the age, creatinine, and ejection fraction (ACEF) score was also
calculated. (10)
Patients’ information and clinical preoperative, intraoperative, and
postoperative data were collected. Categorical variables are reported as
numbers (percentage), whereas continuous variables are expressed as
mean ± standard deviation or as median (interquartile range), according
to the Kolmogorov-Smirnov test. 
Fisher’s test was used to calculate p-values between 2 groups for
categorical variables, whereas Wilcoxon test was used for continuous
variables. 
Multivariate analysis was performed using a stepwise logistic regression.
The set of covariates was based on the univariate logistic model: all the
variables with a p-value < 0.2 were included in the multivariate model. A
further dicotomous variable, the “presence of at least 3 comorbidities”,
was created and tested in the multivariate models. All statistical analyses
were performed with SAS software (release 9.2 by SAS Institute Inc.
Cary, NC, USA).
Results
Eight thousand, one hundred and sixty two microbiological samples were
analyzed for suspicion of infection in the 7,313 patients who underwent
cardiac surgery in the study period. The majority of samples (72%) had
no microorganism isolated. Staphylococcus spp was the most frequently
isolated germ in our ICU during the study period, with 876 positive
samples out of 8,162. The 876 samples belonged to 339 patients.
Staphylococcus aureus spp were isolated in 338 samples from 124
patients. Infection with MRSA was recorded in 47 microbiological
samples from 28 patients (0.38%). The most frequently isolated germs
are summarized in table 1.
The mean age of the overall study population was 60 ± 13.7 years, and
4,696 (64%) were male. One hundred-sixty three patients (2.2%) died.
The number of patients with MRSA infection, stratified according to
years, was always below 1% and is reported in figure 1. Mortality in
patients with MRSA infection over the years 2003-2009 was 80% (4 out
of 5 patients), 67% (2 out of 3 patients), 50% (1 out of 2 patient), 37% (4
out of 11 patients), 0% (0 out of 1 patient), 40% (2 out of 5 patients), and
100% (1 patient), respectively.
Baseline, intraoperative and postoperative data of patients with MRSA
infection compared to patients without MRSA infection are reported in
table 2. Mortality was 50% in patients with MRSA infection, and 2% in
patients without MRSA infection (p<0.001). Baseline, intraoperative and
postoperative data of patients who survived, compared to patients who
died during hospitalization, is shown in table 3.
The site of MRSA isolation is shown in detail in table 4, together with MR
not-Aureus Staphylococci. The most frequent site of MRSA isolation was
from bronchoalveolar secretions (21 cases). On the contrary, not-Aureus
MR Staphylococci were most frequently found in blood samples (100
cases). Multivariate analysis of preoperative and intraoperative factors
which were significantly associated with MRSA positivity is shown in
table 5.
Table 6 displays the results of multivariate analysis on preoperative and
intraoperative factors significantly associated with hospital mortality.
Notably, MRSA infection was the strongest predictor of mortality with an
odds ratio of 20.5 (95% CI 4.143-101.626).
Discussion
This study analyzed all the patients who underwent cardiac surgery at our
institution over a six-year period, focusing on the development of MRSA
infections during the cardiac Intensive Care Unit stay. These data are to
be compared with those from our previous study conducted between 1997
and 2003 in the same center and enrolling similar patients. First of all,
MRSA was observed with a prevalence rate below 1% in the whole study
period, compared to the 2% of the pre-existing study. Furthermore, a
strong association between MRSA isolation and in-hospital mortality (OR
8.5, 95% CI 4.9-14.7) was observed in 1997-2003 patients. (1) This
observation is further reinforced by the consideration that our center has
a very low perioperative mortality rate, as recently highlighted. (11) Our
study confirmed that infection with MRSA is an independent predictor of
mortality ( OR 20.5, 95% CI 4.143-101.626) but notably the incidence of
MRSA infection recorded is lower compared to the previous population
(28 patients).
The issue of MRSA infections in the ICU is greatly discussed in the
literature. An observational cohort study, dated 2010, and including
4,949 patients with Staphylococcus aureus infection, was conducted to
evaluate the clinical impact of methicillin resistance on outcome of
patients and concluded that S. aureus infections did not adversely affect
the outcome. (12) It is presumed that infections caused by MRSA result in
higher mortality, longer hospitalization, and greater costs than infections
caused by methicillin-susceptible Staphylococcus aureus (MSSA).
However, the impact of MRSA on mortality is not easy to determine. The
outcomes of infections indeed might depend on individual variables such
as underlying medical conditions, treatments administered before
surgery, and inappropriate antibiotics use to eradicate postoperative
infections, resulting in increased bacterial resistance.
Our study included patients who received preoperative antibiotic
prophylaxis according to the protocol adopted by the center, also in line
with the latest reports that confirm that administration of antibiotic
prophylaxis in cardiac surgery might reduce the development of both
superficial skin and wound infections. (13) In 2013, a systematic
literature review and meta-analysis (14) of factors associated with MRSA
colonization at time of hospitalization or intensive care unit admission
was conducted, including articles from 1966 to 2012, in order to
underline how the definition of high risk can differ among hospitals and
state laws. Many hospitals screen for MRSA colonization on admission as
a key infection prevention strategy. An alternative to universal screening
is to test for MRSA among populations at high risk for colonization, but
such an approach can be hard on resources and may pose practical
challenges. However, it is common agreement that active MRSA
surveillance, combined with implementation of barrier precautions, with
or without decolonization protocols, has been associated with reduced
MRSA transmission in investigations conducted in high prevalence
settings. (14) A clear representation of MRSA trend in each centre is
surely pivotal to refine the growing practice of MRSA surveillance
programs, especially in a cardiac ICU where the critically ill patient’s
condition is the humus for growing risk factors that might be strictly
controlled.
We also performed a multivariate analysis in order to identify factors
associated with MRSA infection and in-hospital mortality. Despite some
differences in the results between the two populations, MRSA infection
was confirmed to be an independent predictor of mortality in the 2003-
2009 population also.
This observation suggests that, although MRSA infection rate is
decreasing, the occurrence of such a complication is still not easy to
handle, therefore strong efforts should be made to prevent it. An
interesting finding was also the fact that the patients undergoing diuretic
therapy before surgery presented a higher risk for MRSA infection. This
is not a surprising result, even though the scientific evidence in this field
is still limited. Furosemide indeed was already shown to have
immunosuppressive effects on peripheral blood mononuclear cells which
are similar to equimolar concentrations, hence, equivalent doses of
hydrocortisone. (15)
Another interesting element to comment on is the evaluation of the most
typical site of MRSA isolation that remained bronchial secretions for both
studies (32 isolations for the previous study conducted in 1997-2003 and
21 for the second one during 2003-2009).
Finally, we also observed a non- negligible rate of fungal infections,
especially by Candida spp. Although the prevalence of fungal infections
and their impact on survival are beyond the scope of this study, this
observation may suggest watchful monitoring in the future.
Based on our data, it is reasonable to conclude that a few elements at
baseline may help to stratify which patients are at increased risk of MRSA
infection and hospital mortality.
A perception exists that longer ICU stay is directly related to in-hospital
mortality, but this supposition is not fully validated in cardiac surgery
patients. An effort to characterize postoperative length of ICU stay and to
match it with demographic data, preoperative comorbidities, and
postoperative complications has been done by a team of anesthesiologists
between 2004 and 2012. They collected data of patients that underwent
cardiac surgery and demonstrated that, for this cohort of patients, it
remained unclear how much the likelihood for mortality increased after
each postoperative day in the ICU or hospital. (16)
Our study has some limitations. First, it included patients from a single
center and therefore the results cannot be applied to all ICUs, because of
the differences in strategies adopted in the prevention and in the control
of MRSA infections among ICUs and cardiac ICUs as well as in the
different surveillance protocols existing in the various centers. On the
other hand, this study represents a valid frame for the evolution of MRSA
trend in our center and specifically in our cardiac ICU, defining a
continuous state of MRSA infections in the last 2 decades. Another
limitation of this study is the lack of a surveillance protocol for isolation
of pathogens and decolonization of patients admitted to the ICU. Indeed,
a recent paper gives a landmark for what concerns decolonization to
prevent ICU infections. Specifically, both targeted and universal
decolonization of patients were adopted in a cluster-randomized trial,
and universal decolonization significantly reduced the rate of all
bloodstream infections in ICU practice than either targeted
decolonization or screening and isolation. (6)
CONCLUSION
MRSA infections in our experience are less common than in the past, yet
they still have a strong impact on the patients’ outcome. Therefore,
efforts should be directed toward the development of new risk analysis
models that might implement health care practices and might become
precious instruments for infection prevention and control.
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Figure 1. Patients with Methicillin-resistant Staphylococcus Aureus
(MRSA) infection per year.
Table 1. The most frequently isolated germs in our Intensive Care Unit
(ICU) in the 6-year study period.
Microorganism Frequency(percentage)
Staphylococcus spp 876 (38.4)
> Staphylococcus aureus 338 (14.8%)
> Staphylococcus aureus MR 256 (11.2%)
> Staphylococcus non aureus spp 538 (23.6%)
> Staphylococcus non aureus MR
spp 489 (21.4%)
Candida spp 300 (13)
Pseudomonas spp 272 (11.9)
Escherichia spp 134 (5.9)
Enterobacter spp 120 (5.3)
Serratia spp 105 (4.6)
Klebsiella spp 91 (4)
Enterococcus spp 74 (3.2)
Corynebacterium spp 50 (2.2)
Stenotrophomonas spp 47 (2)
Citrobacter spp 33 (1.4)
Proteus spp 33 (1.4)
Haemophilus spp 20 (0.9)
Streptococcus spp 20 (0.9)
Aspergillus spp 18 (0.8)
Acinetobacter spp 14 (0.6)
Morganella spp 14 (0.6)
Table 2. Baseline, intraoperative, and postoperative data of patients
with and without Methicillin-resistant Staphylococcus Aureus (MRSA)
infection. Continuous data are presented as media ± standard deviation,







Male gender, n 4678 (64%) 18 (64%) 0.9
Age, years 60 ± 13.7 68 ± 12.7 0.007
Height, cm 169 ± 9.2 169 ± 9.2 0.7
Weight, kg 72 ± 13.7 73 ± 19.2 0.7
BMI 25.3 ± 4 25.8 ± 6.3 0.9
Comorbidity
> Active smoking, n 863 (12%) 3 (11%) 0.9
> COPD, n 1086 (15%) 16 (57%) <0.001
> Ejection fraction, % 55.6 ± 10.2 48.7 ±12.8 0.009
> Ejection fraction <= 40%, n 773 (12%) 8 (36%) 0.003
> Vasculopathy, n 1095 (15%) 9 (32%) 0.018
> Arterial hypertension, n 2697 (37%) 9 (32%) 0.6
> Diabetes, n 722 (9.9%) 5 (18%) 0.2
> Angina, n 499 (6.9%) 2 (7.1%) 0.9
> Acute myocardial
infarction, n 675 (9.3%) 2 (7.1%) 0.8
> Euroscore standard 4 (3 – 6) 7 (5 – 9) 0.001
> ACEF mortality risk 1.9 (1.4 – 2.4) 2.5 (2 –7.86) 0.0012
> Creatinine clearance, ml/h 78.7 (60.4 –101.1)
55.5 (38.8
– 71.9) 0.0014
> Stroke or transient ischemic
attack, n 402 (5.5%) 2 (7.1%) 0.9
> Active bacterial
endocarditis, n
137 (1.9%) 1 (3.6%) 0.9
> Creatinine, mg/dl 0.98 ± 0.58 1.68 ±1.48 0.001
NYHA 0.006
> I, n 984 (20%) 1 (5%)
> II, n 2518 (51%) 7 (37%)
> III, n 1322 (27%) 9 (47%)
> IV, n 79 (2%) 2 (11%)
Preoperative IABP, n 189 (2.6%) 3 (11%) 0.036
Timing of surgery <0.001
> Emergency, n 79 (1%) 1 (4%)
> Urgency, n 383 (5%) 8 (29%)
> Election, n 6823 (94%) 19 (68%)
Redo surgery, n 568 (7.8%) 7 (25%) 0.005
Antiplatelets, n 1516 (21%) 7 (25%) 0.6
Inotropes, n 37 (0.51%) 1 (3.6%) 0.14
Diuretics, n 2639 (36%) 19 (68%) <0.001
Betablockers, n 2560 (35%) 8 (29%) 0.6
Antiarrhythmics, n 757 (10%) 2 (7.1%) 0.8
Antibiotics, n 205 (2.8%) 2 (7.1%) 0.18
Calcium channel antagonists,
n 1026 (14%) 4 (14%) 0.9
Nitrates,n 842 (12%) 4 (14%) 0.8
ACE inhibitors, n 3197 (44%) 7 (25%) 0.055
Oral anticoagulants, n 995 (14%) 4 (14%) 0.9
Heparin, n 322 (4.4%) 2 (7.1%) 0.6
Previous cardiac surgery, n 417 (5.7%) 3 (10.7%) 0.4
Bilirubin, mg/dl 0.8 (0.6 – 1.1) 1.01 (0.66– 1.51) 0.17
Intraoperative data
CPB, n 6778 (94%) 25 (100%) 0.4
Cardioplegy, n 2838 (39%) 10 (36%) 0.8
Duration of aortic clamping,
min 59 (47 – 75)
73 (55 –
98) 0.07
Duration of CPB, min 76 (62 – 95) 94 (90 –104) 0.027
Outcomes
Death, n 149 (2.05%) 14 (50%) <0.001
ICU stay, days 1 (1 – 3) 20 (12 –39) <0.001
Hospital stay, days 6 (4 – 8) 42 ( 18 –54) <0.001
Creatinine peak, mg/dl 0.9 (0.75 –1.12)
1.03 (0.77
– 1.72) 0.1






Total blood loss, ml 350 (220 –500)
545 (350
– 610) 0.11
CVVH, n 139 (1.9%) 10 (36%) <0.001
RBC transfusions, n 0 (0 – 0)
2.5 (0 –
7.5) <0.001
FFP transfusions, n 0 (0 – 0) 0 (0 – 2) <0.001
PLT transfusions, n 0 (0 – 0) 0 (0 – 0) <0.001
Hemoderivates, n 1516 (21%) 18 (64%) <0.001
Mechanical ventilation, hours 12 (8 – 16) 240 (72 –360)
<
0.001
Neurologic injury type 1*, n 86 (1.2%) 2 (7.1%) 0.044
Neurologic injury type 2*, n 110 (1.5%) 1 (3.6%) 0.3
IABP, n 99 (1.4%) 1 (3.6%) 0.3
Perioperative AMI, n 114 (1.6%) 1 (3.6%) 0.4
Troponine peak value, 7.9 (4.8 – 13) 18.7 (5.2 –31.6) 0.045
Atrial fibrillation, n 1242 (17%) 13 (46%) <0.001
Tracheostomy, n 85 (1.2%) 14 (50%) <0.001
Reintubation, n 91 (1.3%) 12 (43%) <0.001
Cardiogenic shock, n 148 (2%) 8 (29%) <0.001
Inotropes more than 48
hours, n 701 (9.6%) 13 (46%)
<
0.001
Pulmonary dysfunction, n 418 (5.7%) 16 (57%) <0.001
ACE, angiotensin converting enzyme; ACEF, age, creatinine, ejection
fraction; AMI, acute myocardial infarction; BMI, body mass index;
COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary
bypass; CVVH, continuous venovenous hemofiltration; FFP, fresh frozen
plasma; LCOS, low cardiac output syndrome; MRSA, Methicillin
Resistant Staphylococcus Aureus; IABP, intraaortic balloon pump; ICU,
intensive care unit; NYHA, New York Heart Association; PLT, platelets;
RBC, red blood cells.
* Neurologic damage type I is defined as death due to stroke or hypoxic
encephalopathy, new nonfatal stroke, or transient ischemic attack (TIA),
or stupor or coma at the time of discharge. By neurologic damage type II
we mean a new deterioration in intellectual function, confusion,
agitation, disorientation, memory deficit, or a nonmetabolic seizure
without evidence of focal injury. (17)
Table 3. Baseline, intraoperative, and postoperative data of patients who
survived compared to patients who died during hospitalization.
Continuous data are presented as media ± standard deviation, and






Male gender, n 4603 (64%) 93 (57%) 0.054
Age, years 60 ± 13.7 69 ± 10.3 <0.001
Height, cm 169 ± 9.2 165 ± 9 <0.001
Weight, kg 72 ± 13.7 70 ± 15.9 0.03
BMI 25.3 ± 4 25.5 ± 5.1 0.8
Comorbidity
> Active smoking, n 856 (12%) 10 (6.1%) 0.026
> COPD, n 1017 (14%) 85 (52%) <0.001
> Ejection fraction, % 55.8 ± 10.1 46.5 ± 13.5 <0.001
> Ejection fraction <= 40%, n 737 (12%) 44 (40%) <0.001
> Vasculopathy, n 1067 (15%) 37 (23%) 0.008
> Arterial hypertension, n 2648 (37%) 58 (36%) 0.7
> Diabetes, n 702 (9.8%) 25 (15%) 0.024
> Angina, n 488 (6.8%) 13 (8%) 0.6
> Acute myocardial infarction,
n 648 (9.1%) 29 (18%) <0.001
> Euroscore standard 4 (3 – 6) 7 (6 -9) <0.001










> Stroke or transient ischemic
attack, n, n 395 (5.5%) 9 (5.5%) 0.5
> Active bacterial endocarditis,
n 132 (1.9%) 6 (3.7%) 0.13
> Creatinine, mg/dl 0.98 ± 0.57 1.38 ± 1.07 <0.001
NYHA <0.001
> I, n 983 (20%) 2 (3%)
> II, n 2504 (52%) 21 (30%)
> III, n 1294 (27%) 37 (53%)
> IV, n 71 (1%) 10 (14%)
Preoperative IABP, n 174 (2.4%) 18 (11%) <0.001
Timing of intervention <0.001
> Emergency 57 (0.8%) 23 (14%)
> Urgency, n 371 (5.2%) 20 (12%)
> Election, n 6722 (94%) 120 (74%)
Redo surgery, n 547 (7.7%) 28 (17%) <0.001
Antiplatelets, n 1498 (21%) 25 (15%) 0.09
Inotropes, n 30 (0.42%) 8 (4.9%) <0.001
Diuretics, n 2575 (36%) 83 (51%) <0.001
Betablockers, n 2526 (35%) 42 (26%) 0.013
Antiarrhytmics, n 733 (10%) 26 (16%) 0.021
Antibiotics, n 195 (2.7%) 12 (7.4%) 0.002
Calcium channel antagonists, 1013 (14%) 17 (10%) 0.21
Nitrates, n 822 (12%) 23 (14%) 0.3
ACE inhibitors, n 3150 (44%) 54 (33%) 0.007
Oral anticoagulants, n 979 (14%) 20 (12%) 0.6
Heparin, n 317 (4.4%) 7 (4.3%) 0.9







CPB, n 6671 (94%) 132 (94%) 0.8
Cardioplegy, n 2801 (39%) 47 (29%) 0.007
Duration of aortic clamping,
min 59 (47 – 75)
68 (50 –
82) 0.02






ICU stay, days 1 (1 – 3) 9 (3 – 19) <0.001
Hospital stay, days 6 (4 – 8) 15 (7 – 33) <0.001













Total blood loss, ml 350 (220 –500)
500 (330 –
770) 0.005
CVVH, n 76 (1.1%) 73 (45%) <0.001
RBC transfusions, n 0 (0 – 0) 2 (0 – 7) <0.001
FFP transfusions, n 0 (0 – 0) 0 (0 – 4) <0.001
Platelet transfusions, n 0 (0 – 0) 0 (0 – 3) <0.001
Hemoderivates, n 1425 (20%) 109 (67%) <0.001
Mechanical ventilation, hours 12 (8 – 16) 72 (28 –264)
<
0.001
Neurologic damage type 1*, n 71 (1%) 17 (10%) <0.001
Neurologic damage type 2*, n 97 (1.4%) 14 (8.6%) <0.001
IABP, n 97 (1.4%) 2 (1.2%) 0.9
Perioperative AMI, n 99 (1.4%) 16 (9.8%) <0.001





Atrial fibrillation, n 1218 (17%) 37 (23%) 0.059
Tracheostomy, n 58 (0.8%) 41 (25%) <0.001
Reintubation, n 69 (0.97%) 34 (21%) <0.001
Cardiogenic shock, n 80 (1.1%) 76 (47%) <0.001
Inotropes more than 48 hours,
n 626 (8.8%) 88 (54%)
<
0.001
Pulmonary dysfunction, n 360 (5%) 74 (45%) <0.001
ACE, angiotensin converting enzyme; ACEF, age, creatinine, ejection
fraction; AMI, acute myocardial infarction; BMI, body mass index;
COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary
bypass; CVVH, continuous venovenous hemofiltration; FFP, fresh frozen
plasma; LCOS, low cardiac output syndrome; MRSA, Methicillin
Resistant Staphylococcus Aureus; IABP, intraaortic balloon pump; ICU,
intensive care unit; NYHA, New York Heart Association; PLT, platelets;
RBC, red blood cells.
* Neurologic damage type I is defined as death due to stroke or hypoxic
encephalopathy, new nonfatal stroke, or transient ischemic attack (TIA),
or stupor or coma at the time of discharge. By neurologic damage type II
we mean a new deterioration in intellectual function, confusion,
agitation, disorientation, memory deficit, or a nonmetabolic seizure
without evidence of focal injury. (17)





secretions, n 21 1
Blood, n 9 100
Central venous catheter,n 7 31
Pleural effusion, n 1 1
Other, n 9 18
MRS, Methicillin Resistant Staphylococcus.
Table 5. Factors associated with Methicillin-resistant Staphylococcus






COPD 4.356 1.382 13.729 0.012




6.301 1.984 20.008 0.002
Redo surgery 4.846 1.527 15.383 0.007
Diuretics 10.012 1.266 79.191 0.029
COPD, chronic obstructive pulmonary disease.





MRSA 20.519 4.143 101.626 0.0002
Acute myocardial
infarction 2.472 1.315 4.646 0.005
Antiarrhythmics 2.454 1.289 4.672 0.006
CVVH 12.219 6.418 23.264 <0.0001
Hemoderivates 2.959 1.612 5.432 0.0005
Neurologic
damage type 2* 4.526 1.718 11.923 0.002
Tracheotomy 2.615 1.097 6.233 0.03
Reintubation 4.629 2.01 10.662 0.0003
Cardiogenic shock 16.665 8.47 32.791 <0.0001
Pulmonary
dysfunction 2.417 1.268 4.61 0.007
CVVH, continuous venovenous hemofiltration; MRSA, Methicillin
Resistant Staphylococcus Aureus.
* Neurologic damage type I is defined as death due to stroke or hypoxic
encephalopathy, new nonfatal stroke, or transient ischemic attack (TIA),
or stupor or coma at the time of discharge. By neurologic damage type II
we mean a new deterioration in intellectual function, confusion,
agitation, disorientation, memory deficit, or a nonmetabolic seizure
without evidence of focal injury. (17)
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